William Sikov

William Sikov is a breast cancer clinical trialist who contributed to neoadjuvant trials in triple-negative breast cancer examining carboplatin addition to standard chemotherapy to improve pathological complete response rates. His work on treatment intensification in the neoadjuvant TNBC setting laid groundwork for subsequent residual disease escalation strategies. He participates in cooperative group trial development and has contributed to ASCO educational programs on neoadjuvant breast cancer. Sikov's research addresses optimal chemotherapy regimen selection for TNBC in the neoadjuvant context.